Evaluation of the Efficacy and Safety of AVANZ® Phleum Pratense in Grass Pollen-induced Allergic Rhinitis During Controlled Exposure in an Environmental Challenge Chamber
PHASE2CompletedINTERVENTIONAL
Enrollment
140
Participants
Timeline
Start Date
June 30, 2014
Primary Completion Date
October 31, 2015
Study Completion Date
October 31, 2015
Conditions
Grass Pollen Induced Allergic Rhinoconjunctivitis
Interventions
DRUG
AVANZ Phleum pratense 15,000 SQ+
DRUG
Placebo
Trial Locations (1)
30625
Fraunhofer Institute, Hanover
All Listed Sponsors
lead
ALK-Abelló A/S
INDUSTRY
NCT02166268 - Evaluation of the Efficacy and Safety of AVANZ® Phleum Pratense in Grass Pollen-induced Allergic Rhinitis During Controlled Exposure in an Environmental Challenge Chamber | Biotech Hunter | Biotech Hunter